The effect of initial duloxetine dosing strategy on nausea in Korean patients with major depressive disorder

Psychiatry Investigation

Volumn 9, Issue 4, 2012, Pages 391-399

  Lee, Min Soo ^a   Ahn, Yong Min ^b   Chung, Seockhoon ^c   Walton, Richard ^d   Raskin, Joel ^e   Kim, Mun Sung ^f  

^a Korea University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Eli Lilly Pty Ltd   (Australia)

^e ELI LILLY AND COMPANY   (United States)

^f Eli Lilly Korea Ltd   (South Korea)

Author keywords

Clinical trial; Duloxetine; Korea; Major depressive disorder; Nausea; Phase IV; Serotonin norepinephrine reuptake inhibitor

Indexed keywords

ALPRAZOLAM; DULOXETINE; LORAZEPAM; ZOLPIDEM;

ADULT; AGE; AGED; AMDP 5 SCORE; ANXIETY; ARTICLE; BODY MASS; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FOOD INTAKE; GASTROINTESTINAL DISEASE; HAMILTON SCALE; HEADACHE; HUMAN; INCIDENCE; INSOMNIA; KOREA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTE; SEDATION; SIDE EFFECT; SWEATING; TREMOR; XEROSTOMIA;

EID: 84871593642     PISSN: 17383684     EISSN: 19763026     Source Type: Journal    
DOI: 10.4306/pi.2012.9.4.391     Document Type: Article

References (15)

1. Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK; Clinical Efficacy Assessment Subcommittee of American College of Physicians. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:725-733.
2. Gartlehner G, Thaler K, Hansen RA, Gaynes BN. The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis. Drug Saf 2009;32:1159-1173.
3. Lee P, Shu L, Xu X, Wang CY, Lee MS, Liu CY, et al. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. Psychiatry Clin Neurosci 2007;61: 295-307.
4. Nelson JC, Lu Pritchett Y, Martynov O, Yu JY, Mallinckrodt CH, Detke MJ. The safety and tolerability of duloxetine compared With paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim Care Companion J Clin Psychiatry 2006;8:212-219.
5. Brunton S, Wang F, Edwards SB, Crucitti AS, Ossanna MJ, Walker DJ, et al. Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies. Drug Saf 2010;33:393-407.
6. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-390.
7. Greist J, McNamara RK, Mallinckrodt CH, Rayamajhi JN, Raskin J. Incidence and duration of anti-depressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 2004;26:1446-1455.
8. Dunner DL, Wohlreich MM, Mallinckrodt CH, Watkin JG, Fava M. Clinical consequences of initial duloxetine dosing strategies: comparison of 30 and 60 mg starting doses. Curr Ther Res 2005;66:522-540.
9. Mallinckrodt CH, Prakash A, Andorn AC, Watkin JG, Wohlreich MM. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006;40:337-348.
10. Whitmyer VG, Dunner DL, Kornstein SG, Meyers AL, Mallinckrodt CH, Wohlreich MM, et al. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. J Clin Psychiatry 2007;68:1921-1930.
11. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
12. Stieglitz RD, Faehndrich E, Helmchen H. The AMDP System. In: Mezzich JE, von Cranach M, Editors. The International Classification in Psychiatry. New York, NY: Cambridge University Press, 1988, p.180-204.
13. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education and Welfare, 1976, p.218-222.
14. Chen PY, Wang SC, Poland RE, Lin KM. Biological variations in depression and anxiety between East and West. CNS Neurosci Ther 2009;15: 283-294.
15. Epstein WV. Expectation bias in rheumatoid arthritis. The anti-CD4 monoclonal antibody experience. Arthritis Rheum 1996;39:1773-1780.